Please login to the form below

Not currently logged in
Email:
Password:

Watson to buy products from Teva's Barr acquisition

Speciality pharmaceutical company Watson has signed an agreement to purchase 17 generic pharmaceutical products from Teva

Speciality pharmaceutical company Watson has signed an agreement to purchase 17 generic pharmaceutical products, 15 of which have FDA-approval, which are being divested as part of Teva's acquisition of Barr Pharmaceuticals.

The product acquisition is subject to Teva's merger with Barr and will see Watson make an upfront payment to Teva of $36m with additional milestone payments throughout the product development stages.

"These products represent a sound complement to our extensive generics portfolio," said Paul Bisaro, president and CEO of Watson. He added: "We anticipate these new generics will have immediate value that we will begin to realise in early 2009."

Teva will supply the products to Watson under a manufacturing and supply agreement until manufacturing is transferred to Watson or a third party.

25th November 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashley Communications

Ashley Communications is a bespoke, independent medical communications consultancy consistently providing a unique director-delivered client service tailored to individual client...

Latest intelligence

What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....

Infographics